Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000426

Drug Information
NameRifapentine    
SynonymsSAM001246620; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; MDL473; CID6323497; DL 473; Cyclopentylrifampicin; HMS2051D16; 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin SV; CHEMBL1660; EINECS 262-743-9; Rifapentinum; Ambap127923-87-9; RPE; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Antibiotic DL 473IT; MDL-473; CPD001906779; Rifapentine (USAN/INN); C08059; DL-473; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; Rifapentina; UNII-XJM390A33U; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-{(E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl}-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; R-773; 71950-35-1; Priftin (TN); CHEBI:45304; MLS001424209; 61379-65-5; 3-[N-(4-Cyclopentyl-1-piperazinyl)formimidoyl]rifamycin; C47H64N4O12; Rifapentin; CID6434610; DL473; M000473; SMR000466332; DB01201; BIDD:GT0669; S1760_Selleck; (2R,16S,17R,18R,19R,20S,21S,22S,23S)-8-{[(4-CYCLOPENTYLPIPERAZIN-1-YL)IMINO]METHYL}-5,6,9,17,19-PENTAHYDROXY-23-METHOXY-2,4,12,16,18,20,22-HEPTAMETHYL-1,11-DIOXO-1,2-DIHYDRO-2,7-(EPOXYPENTADECA[1,11,13]TRIENOIMINO)NAPHTHO[2,1-B]FURAN-21-YL ACETATE; DL-4-73; DL 473-IT; Priftin, Cyclopentylrifampicin, Rifapentine; RPT; RIFAPENTINE; SAM002589953; CID9919168; R 77-3; D00879; Cyclopentyl rifampin; DRG-0283; LS-143825; NCGC00167431-01; MLS000759441; CPD000466332; KTC 1; Rifamycin AF/ACPP; CID6835847; MDL 473; Rifapentina [Spanish]; Rifamycin, 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)-; Rifapentinum [Latin]; Rifapentine [USAN:BAN:INN]; Priftin    
Trade NamePriftin    
CompanySanofi-Aventis    
IndicationTuberculosisApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntituberculosis Agents    
CAS NumberCAS 61379-65-5
FormularC47H64N4O12    
PubChem Compound IDCID 6323497.    
PubChem Substance IDSID 10259.    
ChEBI45304;    
SuperDrug ATC IDJ04AB05;    
SuperDrug CAS ID061379655;    
TargetDNA-dependent RNA polymeraseBinder[2]
Ref 1Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. To Reference
Ref 2Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543